Effect of H2-Receptor Antagonists Cimetidine and Famotidine on Interdigestive Gastric Motor Activity and Lower Esophageal Sphincter Pressure in Progressive Systemic Sclerosis.

Horikoshi, Tsutomu; Matsuzaki, Takashi; Sekiguchi, Toshio

doi:10.2169/internalmedicine.33.407

Cited by 7 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 210 articles were evaluated and 73 were ultimately selected for inclusion in this study (refs 6–77,. and Seibold JR et al: unpublished observations).…”

Section: Resultsmentioning

confidence: 99%

Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment

Villela

Yuen

Pope

et al. 2008

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To determine the generalizability of randomized controlled trials (RCTs) in the treatment of systemic sclerosis (SSc) using the Canadian Scleroderma Research Group (CSRG) database. Methods. We identified articles related to SSc published from 1958 to 2006. Key points on trial design were recorded. The inclusion/exclusion criteria were used in conjunction with the CSRG database to determine the proportion of patients with SSc who would theoretically be eligible for these trials. Articles were classified into subcategories according to the target system. The CSRG database contains 438 patients with SSc from 14 Canadian centers. Results were in median (%) and mean (%) with 95% confidence intervals (95% CIs). Results. In total, 210 articles were evaluated and 73 were selected for inclusion in this study. The mean percentage of eligible patients with SSc associated with other conditions was 35% (95% CI 17-53) for Raynaud's phenomenon, 24% (95% CI 1-47) for digital ulcers, 48% (95% CI 27-68) for gastrointestinal (GI) involvement, 32% (95% CI 20 -43) for overall disease modification, 6% (95% CI 4 -8) for pulmonary arterial hypertension, 2% (95% CI 0 -4) for interstitial lung disease, and 38% (95% CI 12-64) for other categories. Conclusion. Except for GI trials, <38% of the identified patients with SSc would have been suitable to enter the RCTs. Although some patients would be ineligible because they lack certain organ involvement, RCTs designed to include appropriate patients with SSc are needed; there are few proven treatments and trials typically do not include the majority of those who could potentially benefit from the intervention.

show abstract

“…In total, 210 articles were evaluated and 73 were ultimately selected for inclusion in this study (refs 6–77,. and Seibold JR et al: unpublished observations).…”

Section: Resultsmentioning

confidence: 99%

Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment

Villela

Yuen

Pope

et al. 2008

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…However, only famotidine caused a significant esophageal pressure rise in patients without an increase of gastric motility. These findings suggest that the inhibition of lower esophageal acetylcholinesterase activity and gastric acid secretion may be involved in the mechanisms of action of cimetidine and famotidine (70).…”

Section: Management Of Gastrointestinal Manifestationsmentioning

confidence: 96%

“…Cisapride is another 5HT-4 agonist which has been studied in reflux esophagitis in SSc, but has since been withdrawn from the market due to concern for cardiac arrhythmias (69). Cisapride increases acetylcholine release from the myenteric plexus and is thought to increase lower esophageal sphincter pressure and gastric emptying through increases in esophageal contracting amplitudes and in the number of gastric contractions (70). Another high affinity 5HT-4, prucalopride, is still being studied for pro-motility for chronic intestinal pseudo-obstruction (67), but is not yet approved by the U.S. Food and Drug administration.…”

Section: Management Of Gastrointestinal Manifestationsmentioning

confidence: 99%

Gastrointestinal and Hepatic Disease in Systemic Sclerosis

Frech

Mar

2018

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Although classification criteria for systemic sclerosis (SSc) do not incorporate gastrointestinal tract (GIT) manifestations often present in this disease, the GIT is the most common internal organ involved. Pathophysiology of GIT involvement is thought to be similar to other organs in SSc with fibroproliferative vascular lesions of small arteries and arterioles, increased production of profibrotic growth factors, and alterations of innate, humoral, and cellular immunity. These processes result in neuropathy progressing to myopathy with eventual fibrosis. Proper diagnostics and therapeutics for SSc-GIT involvement require the treating physician to have an understanding of an integrated approach and potential medication adverse effects.

show abstract

“…Unfortunately, only a few prospective studies have assessed GIT in SSc [37,38], and these studies have not led to major advances in development of outcome measures. In other words, although assessment of the GIT in SSc remains a challenge, new approaches are promising.…”

Section: Patient-reported Outcome Measurementioning

confidence: 99%

Outcome measures in systemic sclerosis: An update on instruments and current research

Khanna

Merkel²

2007

Curr Rheumatol Rep

View full text Add to dashboard Cite

Substantial progress has been made in the past 10 years in the development and validation of outcome measures and refinement of trial methodology for systemic sclerosis (scleroderma, SSc). These advances in outcome measures have focused mostly on specific organ systems involved in SSc. Many of these new tools have been validated and subsequently adapted for use in multicenter clinical trials. Newer outcome measures in development are intended to more precisely quantify clinically meaningful change in specific organ systems, and some methods aim to assess overall disease burden in SSc. This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development.

show abstract

Effect of H2-Receptor Antagonists Cimetidine and Famotidine on Interdigestive Gastric Motor Activity and Lower Esophageal Sphincter Pressure in Progressive Systemic Sclerosis.

Cited by 7 publications

References 19 publications

Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment

Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment

Gastrointestinal and Hepatic Disease in Systemic Sclerosis

Outcome measures in systemic sclerosis: An update on instruments and current research

Contact Info

Product

Resources

About